Application of alternatively spliced ​​transcripts in determining sensitivity to cell cycle drugs

By detecting and inhibiting the expression of specific transcripts, the bottleneck of the sensitivity evaluation of targeted cell cycle drugs in the prior art is solved, and the sensitivity and resistance of targeted drugs are achieved is achieved, and the therapeutic effect and breasts are improved. Cancer prognosis.

CN115058485BInactive Publication Date: 2024-11-15CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210788159.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-04
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The lack of accurate methods based on the transcript level in the prior art when evaluating the sensitivity of targeted cell cycle drugs, resulting in the precise response bottlenecks of targeted drugs, especially the complexity of alternative splicing regulation, which makes drug sensitivity evaluation slow progress.

Method used

By detecting the expression of specific transcripts ENST00000547281, ENST00000539930 and ENST00000314392, we provide targeted inhibitors to reduce drug resistance, and develop a transcript-based drug sensitivity evaluation system, combining CRISPR/cas9 gene editing technology and a high-throughput sequencing platform , achieve accurate assessment of drug sensitivity.

Benefits of technology

It improves the accuracy of sensitivity assessment for Palbociclib, Ribociclib, Olaparib and mitotic drugs, reduces patients' resistance to these drugs, provides more accurate therapeutic regimens, and improves the prognosis of cancers such as breast cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115058485B_ABST
    Figure CN115058485B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine, and specifically relates to the application of alternative splicing transcripts in determining the sensitivity of cell cycle drugs. To this end, the present invention provides the application of a reagent for detecting the expression amount of ENST00000547281 in the preparation of a product for determining the drug sensitivity of a patient to Palbociclib and Ribociclib.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to the application of alternative splicing transcripts in judging the sensitivity of cell cycle drugs. Background Art

[0002] The cell cycle has a complex regulatory mechanism, and gene expression regulation is an important part of it. Variable splicing causes genes to produce multiple forms of transcripts, which causes genes to show complex functional changes, but the pattern of transcript changes in the cell cycle and its impact on the clinical phenotype of tumors are still unclear. At the same time, targeted cell cycle therapy is a major branch of tumor treatment. Screening of potential highly responsive patients based on target expression is a major bottleneck for the precise response of cell cycle targeted drugs. The effects of the transcripts produced by most target genes on drug sensitivity are not the same. Therefore, the evaluation of targeted drug sensitivity should go deep into the gene transcript level to achieve progress in precision treatment and medication.

[0003] Alternative splicing is an important regulatory link in the RNA maturation process. In this process, a gene is transcribed into pre-mRNA and then sheared and spliced ​​into mature mRNA molecules with different sequences, which ultimately leads to a single gene producing multiple types of functional proteins. Since the discovery and proposal of the split gene model in 1977, it has been found that more than 95% of genes undergo splicing regulation during the transcription into mature RNA. The DNA sequence of a gene is composed of alternating exons and introns. The typical exon sequence length is 100-200bp, and the intron sequence length is mostly greater than 1000bp. During the transcription process, all the exon and intron sequences of the gene will be transcribed to become precursor mRNA, i.e., pre-mRNA. Under the action of the molecular structure with the splicing complex as the core, the intron sequence of pre-mRNA is removed, and the exon sequences are connected to each other to form the sequence of mature mRNA that can eventually be translated into protein. This process of removing introns from pre-mRNA and connecting exons is called RNA splicing, and each type of spliced ​​mature RNA molecule is called a transcript type. During RNA splicing, some introns may be retained in the final mature mRNA. Different exons of a gene may also undergo a similar process with introns, being selectively connected or removed and not appearing in mature mRNA. At the same time, part of the sequence of an intron or exon may be removed or connected to mature mRNA. The occurrence and proportion of these processes vary under different physiological and pathological conditions. This process of selective splicing to form mature mRNA is called alternative splicing. The main types of alternative splicing are skipped exon (SE), alternative 5'splice site (A5SS), alternative 3'splice site (A3SS), mutually exclusive exons (MXE) and retained intron (RI). The existence of alternative splicing regulatory mechanisms leads to a gene being able to produce a large number of mature mRNAs with different sequences, which are then translated into proteins with different forms and functions, which greatly increases the diversity of gene functions and the complexity of molecular regulatory networks.

[0004] The lack of anti-tumor drug sensitivity markers has always been an important bottleneck problem in the clinical treatment of tumors. In recent years, a large number of studies have been increasingly developing new detection markers, mainly including mutations of key genes, amplification deletions, discovery of expression markers, and discovery of multi-gene joint markers. However, the complexity of molecular regulation involved in tumor drug response far exceeds the regulation scope of the above dimensions. Variable splicing regulation is a part of complex regulation, with a wide range of precise regulatory patterns. Since the direct donor of protein expression is the transcript, the splicing pattern of the anti-tumor target molecule directly determines the structural characteristics of the molecule, so the basic unit for evaluating drug sensitivity should not be the gene as a whole, but the transcript. However, due to the complexity of the splicing regulation pattern, which leads to the shortcomings of splicing regulation research and clinical testing, the development of a transcript-based drug sensitivity evaluation system has been slow. Summary of the invention

[0005] During the transcription process, genes can form transcripts of various sequences. The different proteins translated from these transcripts are directly related to whether the drug works. In theory, evaluating drugs based on transcripts rather than genes should be a more accurate method, that is, transcripts present the molecular structure characteristics of drug target proteins more accurately than genes.

[0006] To this end, the present invention provides the following technical solutions:

[0007] In a first aspect, the present invention provides the use of a reagent for detecting the expression amount of ENST00000547281 in the preparation of a product for determining the drug sensitivity of a patient to Palbociclib and Ribociclib.

[0008] More specifically, the ENST00000547281 (ENST00000547281.5) of the present invention is a transcript of CDK4, also known as CDK4-204, and the ENST00000547281 is 825 bp in length and is translated and transcribed to generate a protein of 186 amino acids. The ENST00000547281 transcript is associated with drug resistance to the CDK4 / 6 inhibitors palbociclib and ribociclib, and the higher the expression of the ENST00000547281, the more drug-resistant it is.

[0009] The terms “Palbociclib” and “Ribociclib” are inhibitors of cyclin dependent kinase (CDK) 4 / 6, or CDK4 targeted drugs.

[0010] On the other hand, the present invention provides a use of an inhibitor targeting ENST00000547281 in reducing a patient's resistance to Palbociclib and Ribociclib.

[0011] The inhibitors of the present invention include shRNA, antisense oligonucleotides (ASO), antibodies, antagonists, blockers, siRNA, miRNA, and reagents used in gene editing methods that specifically target ENST00000547281 or its expression products.

[0012] Preferably, the gene editing method comprises the CRISPR / cas9 method.

[0013] On the other hand, the present invention provides the use of a reagent for detecting the expression amount of ENST00000539930 in preparing a product for determining the drug sensitivity of a patient to olaparib and Talazoparib, and in preparing a product for diagnosing whether a subject has cancer or cancer metastasis.

[0014] More specifically, the ENST00000539930 (ENST00000539930.1) of the present invention is a transcript of PARP2, also known as PARP2-210, and the ENST00000539930 is 635 bp in length and is translated and transcribed to generate a protein of 177 amino acids. The ENST00000539930 transcript shows a high level of expression in normal tissues, while in tumor tissues and metastatic lesions, the expression gradually decreases.

[0015] The terms "Olaparib" and "Talazoparib" are PARP inhibitors.

[0016] Preferably, the patient is a cancer patient.

[0017] More preferably, the patient is a breast cancer patient.

[0018] On the other hand, the present invention provides the use of a reagent for detecting the expression amount of ENST00000314392 in the preparation of a product for determining the drug sensitivity of a patient to mitotic drugs.

[0019] More specifically, the ENST00000314392 (ENST00000314392.13) described in the present invention is a transcript of DPM2, which can also be referred to as DPM2-201. The ENST00000314392 is 912 bp in length and is translated and transcribed to generate a protein of 84 amino acids.

[0020] Preferably, the mitotic drugs include docetaxel, paclitaxel, vinblastine, vincristine, and vinorelbine.

[0021] On the other hand, the present invention provides the use of a reagent for detecting the expression level of DPM2 in the preparation of a product for the prognosis of breast cancer patients.

[0022] Specifically, those with low DPM2 expression levels have better prognosis.

[0023] Preferably, the breast cancer includes triple-negative breast cancer.

[0024] Preferably, the prognostic indicators include objective response rate (ORR), partial response (PR), overall survival rate (OS), recurrence free survival (RFS), complete response (CR), time to progression (TTP), disease-free survival (DFS), time to treatment failure (TTF), and response rate (RR).

[0025] Preferably, the prognosis refers to recurrence free survival (RFS).

[0026] As described in the present invention, "cancer" includes bladder cancer, breast cancer (representative cell lines MDA-MB-231, MCF7, and the breast cancer includes triple-negative breast cancer), cervical cancer, colon cancer (including colorectal cancer, representative cell lines HCT116, HCT8), esophageal cancer, esophageal squamous cell carcinoma, head and neck cancer, liver cancer, lung cancer (including small cell lung cancer and non-small cell lung cancer), melanoma, myeloma, rhabdomyosarcoma, inflammatory myofibroblastic tumor, neuroblastoma (including neuroblastoma, neuroblastoma), pancreatic cancer, prostate cancer, kidney cancer, renal cell carcinoma, sarcoma (including osteosarcoma), skin cancer, Skin cancer (including squamous cell carcinoma), gastric cancer, testicular cancer, thyroid cancer, uterine cancer, mesothelioma, bile duct cancer, leiomyosarcoma, liposarcoma, nasopharyngeal carcinoma, neuroendocrine cancer, ovarian cancer, salivary gland cancer, metastases caused by spindle cell carcinoma, anaplastic large cell lymphoma, anaplastic thyroid cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, and hematological malignancies, such as acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML).

[0027] Preferably, the reagent for detecting expression level of the present invention includes a reagent for detecting protein expression level and / or mRNA expression level.

[0028] Preferably, the reagents for detecting protein expression include reagents used in the following methods: hematoxylin-eosin staining (also referred to as HE staining), safranin O-fast green staining, protein blotting (Western Blot method), enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), sandwich assay, immunohistochemistry (Immunohistochemistry) staining method, mass spectrometry, immunoprecipitation analysis, complement fixation analysis, flow cytometry fluorescence separation technology and protein chip method.

[0029] Preferably, the reagents for detecting the mRNA expression amount include reagents used in the following methods: PCR-based detection method, Southern hybridization method, Northern hybridization method, dot hybridization method, fluorescence in situ hybridization method, DNA microarray method, ASO method, and high-throughput sequencing platform method.

[0030] Preferably, the high-throughput sequencing platform method includes a second-generation sequencing technology for RNA, namely, RNA-seq technology.

[0031] Preferably, the PCR-based detection method includes qPCR (real-time fluorescence quantitative PCR), Real-time qPCR (real-time quantitative PCR), and quantitative reverse transcription polymerase chain reaction (qRT-PCR); in addition, the PCR-based detection method may also include reverse transcription PCR (RT-PCR), in situ PCR, ligase chain reaction (LCR), labeled PCR (LP-PCR), reverse PCR (reverse PCR, amplifying unknown sequences outside the two primers), asymmetric PCR, touchdown PCR, recombinant PCR, nested PCR, multiplex PCR, immuno-PCR, mRNA differential PCR, strand displacement amplification (SDA), nucleic acid sequence-based amplification (NASBA), transcription-based amplification system (TAS), Q-beta replicase (Q-beta PCR), and PCR-based amplification (SDA). replicase) catalyzes RNA amplification, rolling circle amplification (RCA), loop mediated isothermal amplification (LAMP), etc.

[0032] Preferably, the reagents used in the PCR-based detection method may include nucleic acid probes and specific primers; more preferably, the kit may also include commonly used reagents required for the corresponding PCR technology, such as dNTPs, MgCl2, double distilled water, fluorescent probes, etc. These commonly used reagents are well known to those skilled in the art, and there are also standards and controls (such as transcript standards and blank controls, etc.).

[0033] Preferably, the nucleic acid probe can be a single-labeled nucleic acid probe, such as a radionuclide (such as 32P, 3H, 35S, etc.) labeled probe, a biotin-labeled probe, a horseradish peroxidase-labeled probe, a digoxigenin-labeled probe, or a fluorescent group (such as FITC, FAM, TET, HEX, TAMRA, Cy3, Cy5, etc.) labeled probe; the nucleic acid probe can also be a dual-labeled nucleic acid probe, such as a Taqman probe, a molecular beacon, a displacement probe, a scorpion primer probe, a QUAL probe, a FRET probe, etc.

[0034] Preferably, the reagents include specific primers.

[0035] The term "primer", as used herein, means any nucleic acid used in conjunction with initial nucleic acid synthesis and template processing. In a particular embodiment, a primer is an oligonucleotide having a length of 10 to 20 or 30 base pairs. The primer may be in a double-stranded or single-stranded form, with the single-stranded form being preferred.

[0036] Preferably, when distinguishing the expression levels of two transcripts, the design principles of specific primers are as follows:

[0037] 1. When the splicing sequence is less than 300 bp and the expression abundance of the two splicing transcripts does not exceed 90%, upstream and downstream primers are designed for the unspliced ​​sequences on both sides of the splicing sequence. After conventional PCR, the samples are analyzed by agarose gel electrophoresis to analyze the relative abundance of the two transcripts.

[0038] 2. If the splicing sequence is longer than 300bp, design a 5' primer upstream of the splicing sequence, and design a 3' primer downstream of the splicing sequence to ensure that the PCR products of the two 3' primers and the 5' primer are different in length. However, the longest product should not be too long to avoid affecting the PCR efficiency.

[0039] When the expression abundance of the two spliced ​​transcripts does not exceed 90%, the three primers can be mixed in a specific ratio and the samples can be analyzed by agarose gel electrophoresis after conventional PCR. When the expression abundance of the two spliced ​​transcripts differs too much, the two 3' end primers need to be mixed with the 5' end primer for PCR and subsequent detection;

[0040] 3. For other complex spliced ​​transcripts, primers were designed using small sequence differences upstream and downstream of the splicing site, and a two-primer system was used for PCR reaction. In experiments with two transcript target products in one system, agarose gel electrophoresis was used to analyze the relative change ratio, and in experiments with a single transcript target product, qPCR was used for quantitative analysis.

[0041] The term "expression" also refers to gene expression, which refers to the process of synthesizing genetic information from genes into functional gene products. Gene expression products usually include mRNA and proteins. All known life uses gene expression to synthesize macromolecules of life.

[0042] Preferably, the sample comprises: peripheral blood, tissue, blood, serum, plasma, urine, saliva, semen, milk, cerebrospinal fluid, tears, sputum, mucus, lymph, cytosol, ascites, pleural effusion, amniotic fluid, bladder washing fluid and bronchoalveolar lavage fluid.

[0043] Preferably, the sample comprises cells or tissues taken from a tumor site (cancer tissue). BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 The results of the analysis of the relationship between CDK4 splicing and drug sensitivity. A. Scatter plot of the drug sensitivity correlation between CDK4 and ENST00000547281 and Palbociclib and Ribociclib. The X-axis is the IC50 value of Palbociclib and Ribociclib in each cell line in the GDSC database, and the Y-axis is the expression level of CDK4 and ENST00000547281 in each cell line in the CCLE database; B. Splicing pattern diagram of all CDK4 transcripts.

[0045] Figure 2 The results of the analysis of the resistance of cells to CDK4 / 6 inhibitors regulated by ENST00000547281 are shown in Figure 1. A. Sequencing identification diagram of ENST00000547281 and ENST00000257904 transcripts after they were constructed into the pcDNA3.1 vector. The black marked position in the figure shows that ENST00000547281 lacks the exon 2 sequence; B. Electrophoresis analysis diagram of ENST00000547281 and ENST00000257904 identification; C. The degree of absorbance change of cells detected by MTS. The absorbance change values ​​of all cells tested with drugs were standardized by the group without drugs. Figure 3 The results of the analysis of the relationship between PARP2 transcripts and drug sensitivity are shown in Figure 1. A. Scatter plot of the correlation between PARP2 and its transcript ENST00000539930 and the drug sensitivity of Olaparib and Talazoparib; B. The left side shows the classification of PARP2 transcripts and the protein domain information, and the right side shows the correlation coefficient of each PARP2 transcript to the IC50 of Olaparib in ovarian cancer cell lines; C. The expression pattern of different PARP2 transcripts in the samples. Figure 4 This is the tissue expression distribution map of ENST00000539930. The expression distribution of PARP2 transcript ENST00000539930 in various types of tissues in TCGA.

[0046] Figure 5It is a mitosis-related drug sensitivity analysis of periodic transcripts. A. The bubble chart shows the correlation between DPM2 and ENST00000314392 and four drugs: docetaxel, paclitaxel, vincristine, and vinorelbine; B. The periodic expression of DPM2 and ENST00000314392 in Hela cells; C. The periodic expression of DPM2 and ENST00000314392 in MDA-MB-231 cells.

[0047] Figure 6 It is the verification of M phase arrest cycle and DPM2 survival analysis. A. Cell cycle distribution diagram of MDA-MB-231 after G1 / S phase cell cycle synchronization and then blocked by nocodazol for 0-6 hours, P3 / 4 / 5 are the proportions of G1, S, G2 / M phase cells respectively; B. FPKM curves of TOP2A, CENPF, CCNA2, and RAD9A under G2 / M phase arrest, the long line is the FPKM value without blockage, and the short line is the FPKM value after blockage; C. Comparison of FPKM curves of ENST00000314392 under metaphase blockage and without blockage; D / E. RFS curves of DPM2 in breast cancer and triple-negative breast cancer. DETAILED DESCRIPTION

[0048] The present invention is further described below in conjunction with the embodiments. The following description is only a preferred embodiment of the present invention, and does not limit the present invention in other forms. Any technician familiar with the profession may use the above disclosed technical content to change it into an equivalent embodiment with equivalent changes. Any simple modification or equivalent change made to the following embodiments based on the technical essence of the present invention without departing from the content of the present invention falls within the protection scope of the present invention.

[0049] General Methods

[0050] GDSC library: https: / / www.cancerrxgene.org /

[0051] The IC50 values ​​of various drugs for all cell lines were downloaded from the GDSC database, and the IC50 values ​​of GDSC1 and GDSC2 were analyzed separately. The target gene information of drugs was mainly based on the information provided by the GDSC database, and pan-target drugs and cell lines without specific target drug evaluation were deleted.

[0052] CCLE library: https: / / depmap.org / portal /

[0053] The transcriptome expression levels of all cell lines were downloaded from the CCLE database. CCLE matched cells to GDSC1 and GDSC2, respectively. The genes and transcripts were the sum of the drug targets of GDSC1 and 2.

[0054] Drug sensitivity transcript screening

[0055] This study analyzed the transcripts of drug target genes. In order to identify the relationship between transcript expression and corresponding drug sensitivity, we developed a process to automatically match drugs and their corresponding target gene transcripts, and perform Spearman and Pearson correlation analysis and screening on drug IC50 and matched transcripts. We first used GDSC data to establish a cell-drug IC50 matrix, and used CCLE data to establish a cell-gene / transcript expression matrix, and input the two matrices into the process. The process logic is: by matching the drugs and corresponding target genes / transcripts in the two matrices one by one, comparing the correlation between drug IC50 and genes / transcripts in multiple cells, and obtaining the correlation coefficients of all drug target genes / transcripts with drug sensitivity, we then compared the correlation coefficients of the transcripts and their corresponding genes. If the correlation coefficient of the transcript exceeds the absolute value of the correlation coefficient of its corresponding gene by more than 0.1, the transcript is screened as a drug-sensitive transcript.

[0056] Transcript expression pattern analysis

[0057] To analyze the differences in expression patterns among multiple transcripts of a gene, we extracted transcript expression information from CCLE, removed the expression information of cell lines not included in the GDSC dataset, constructed a cell-gene expression matrix, and used GENE-E to perform hierarchical clustering and draw heatmaps for visual analysis.

[0058] Example 1: Use of ENST00000547281 in palbociclib and ribociclib drug resistance

[0059] The main target of Palbociclib and Ribociclib is CDK4. The ENST00000547281 transcript of CDK4 lacks the translation of exons 1, 2, and 7 relative to the reference transcript ENST00000257904 of CDK4 ( Figure 1 B), the transcript's correlation with drug sensitivity to Palbociclib and Ribociclib was significantly better than the overall gene assessment ( Figure 1 A).

[0060] Furthermore, we synthesized the transcript sequence (the sequence of the ENST00000547281 transcript is:), constructed a transcript expression plasmid based on the pcDNA3.1 vector, transfected the plasmid into breast cancer MCF7 cells, and added ribociclib for verification. The results showed that ENST00000547281 significantly improved the drug resistance of cells compared with the CDK4 reference transcript ENST00000257904 group. The multi-layer drug concentration experiment showed that the absorbance change level of the ENST00000547281 group was significantly lower than that of the ENST00000257904 group ( Figure 2 C). These results further confirmed that the expression of specific transcripts is closely related to cell cycle-related drug resistance.

[0061] Example 2. Role of PARP2 transcript ENST00000539930 in olaparib and talazoparib drug resistance effect

[0062] Our analysis found that among all PARP2 transcripts, the expression of ENST00000539930 had the highest correlation with the drug sensitivity of Olaparib and Talazoparib in tumor cells ( Figure 3A). Compared with the reference transcript of PARP2, the ENST00000539930 transcript of the PARP2 gene lacks exons 1-9 and skips exon 15 ( Figure 3 B). To further analyze the relationship between the protein domain encoded by this transcript and drug sensitivity, we conducted further drug sensitivity analysis on all PARP2 transcripts in ovarian cancer. Ovarian cancer is the most common cancer type for PARP inhibitors. We used the expression levels of 11 PARP2 transcripts in ovarian cancer cell lines in the CCLE dataset and the IC50 of Olaparib against tumor cells in GDSC to calculate the Spearman correlation coefficient.

[0063] The results showed that the expression of all transcripts containing and expressing the PARP catalytic domain was negatively correlated with IC50, while other transcripts were positively correlated with IC50. In the single type of ovarian cancer, ENST00000539930 was still the transcript most negatively correlated with Olaparib IC50 ( Figure 3 B). Hierarchical clustering of the expression levels of 11 PARP2 transcripts and the entire gene in different cells in the CCLE dataset showed that ENST00000539930 showed a significantly different expression pattern from other types of transcripts, which explained the difference in correlation coefficients between ENST00000539930 and other types of transcripts and suggested that ENST00000539930 had a high degree of discrimination in drug sensitivity analysis based on PARP2 expression ( Figure 3 C).

[0064] The tsvdb database is a transcript splicing analysis tool specifically for TCGA data established in 2018. It conducts in-depth analysis of gene splicing and transcript forms based on the 2016 update of the TCGA dataset. We analyzed the tsvdb database and found that the ENST00000539930 transcript was also identified in the transcript analysis of GTEx and TCGA data. Compared with the control, its expression in tumors was reduced, and the expression in metastatic lesions showed a further downward trend ( Figure 4 ).

[0065] Example 3: DPM2 transcript ENST00000314392 in mitosis regulation chemotherapy drugs docetaxel and taxane Application of alcohol, vincristine, and vinorelbine in drug resistance

[0066] Targeting the mitotic process is an important means for drugs to fight tumors. We extracted the expression level of the ENST00000314392 transcript of DPM2 in each cell type from the RNA-seq dataset of CCLE, extracted the IC50 of each cell type to paclitaxel, docetaxel, vincristine, and vinorelbine from the GDSC database, and analyzed the correlation coefficient between the expression level of DPM2 and ENST00000314392 and IC50 in all cells.

[0067] The ENST00000314392 transcript of this gene was significantly correlated with four cell cycle regulating chemotherapy drugs, Docetaxel, Pacitaxel, Vincritine and Vinorelbine (p<0.05), which was significantly higher than the correlation between the overall expression of the DPM2 gene and these four drugs ( Figure 5 A).

[0068] Further analysis using our self-built periodic transcript expression matrix revealed that in Hela and MDA-MB-231 cells, the expression of ENST00000314392 during cell mitosis was significantly different from that of DPM2, with the expression level increasing and decreasing after mitosis ( Figure 5 BC). We performed nocodazole arrest on the synchronized cells when they were released from the G1 / S phase, and added Actinomycin D to block RNA synthesis when the cells began to enter the M phase in large numbers. Samples were collected 0, 1.5, 3, 4.5, and 6 hours after the addition of actinomycin D for RNA-seq analysis. Flow cytometry analysis showed that a certain proportion of all samples collected were stably maintained in the M phase ( Figure 6 A). The extraction and analysis of some cell division characteristic genes showed that these genes were stable at a certain expression level and gradually decreased ( Figure 6 B) These results suggest that the expression patterns of periodic transcripts can be verified by RNA-seq analysis after cell cycle arrest.

[0069] For the DPM2 gene, the data analysis showed that after cell division arrest, the expression level of ENST00000314392 transcript increased significantly ( Figure 6C) Since we inhibited transcription during cell cycle arrest, the increased expression of ENST00000314392 was caused by changes in splicing regulation during cell division. This result is consistent with the periodic transcript expression matrix data, which clarifies the phenomenon that ENST00000314392 increases its expression level through alternative splicing during mitosis. The DPM2 gene showed obvious regulation of transcript expression during mitosis, and ENST00000314392 showed obvious correlation with mitotic drug resistance.

[0070] Survival analysis using the KMPLOT breast cancer dataset showed that high expression of DPM2 was significantly associated with poor RFS in breast cancer and triple-negative breast cancer ( Figure 6 D, E).

Claims

1. Application of a reagent for detecting the expression level of ENST00000547281 in the preparation of a product for determining the drug sensitivity of breast cancer patients to Palbociclib and Ribociclib.

2. The use according to claim 1, wherein the detection is performed on a sample, wherein the sample include: Tissue, blood, serum, plasma, urine, saliva, semen, breast milk, cerebrospinal fluid, tears, sputum, cytosol, ascites, pleural effusion, amniotic fluid, bladder washings and bronchoalveolar lavage fluid.

3. The use according to claim 1, wherein the reagent for detecting expression level comprises a reagent for detecting protein expression level and / or mRNA expression level.

4. The use as claimed in claim 3, wherein the reagents for detecting protein expression include reagents used in the following methods: hematoxylin-eosin staining, safranin O-fast green staining, protein blotting, enzyme-linked immunosorbent assay, radioimmunoassay, sandwich assay, immunohistochemical staining method, mass spectrometry, immunoprecipitation analysis, complement fixation analysis, flow cytometry fluorescence separation technology and protein chip method.

5. The use according to claim 3, wherein the reagent for detecting the mRNA expression level includes reagents used in the following methods: PCR-based detection method, Southern hybridization method, Northern hybridization method, dot hybridization method, fluorescence in situ hybridization method, DNA microarray method, ASO method, and high-throughput sequencing platform method.

6. The use as claimed in claim 5, wherein the high-throughput sequencing platform method includes a second-generation sequencing technology for RNA, namely RNA-seq technology.